Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

7.8K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
7.8K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

15.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
15.6K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

9.7K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.7K
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

6.0K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.0K
Immune Surveillance by NK Cells and Phagocytes01:25

Immune Surveillance by NK Cells and Phagocytes

7.6K
Immune surveillance is an integral part of the innate immune system, involving the continuous monitoring of peripheral tissues to detect and respond to pathogens, infected cells, or cancerous cells. This surveillance is conducted primarily by natural killer (NK) cells and phagocytes, which employ distinct but complementary mechanisms to identify and eliminate threats.
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response.

Gut microbes·2026
Same author

Diet-microbiome synergy underlies obesity-associated immunotherapy efficacy.

Nature·2026
Same author

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026
Same author

Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.

Nature medicine·2026
Same author

Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Liquid Biopsy Monitoring in <i>BRAF</i> V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020).

JCO precision oncology·2026

Related Experiment Video

Updated: Dec 21, 2025

Measuring Mitochondrial Function of Na&#239;ve and Effector CD8 T Cells
06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

862

New pathways in immune stimulation: targeting OX40.

Carolina Alves Costa Silva1, Francesco Facchinetti2, Bertrand Routy3

  • 1Departement de la Recherche, Gustave Roussy Institute, Villejuif, France.

ESMO Open
|May 12, 2020
PubMed
Summary

Immune checkpoint blockers (ICB) show promise in cancer treatment but face resistance. Targeting the OX40 molecule offers a new strategy to enhance immune responses against tumors, potentially improving patient outcomes.

Keywords:
OX40OX40LT cellscancerimmunotherapy

More Related Videos

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.1K
Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.1K

Related Experiment Videos

Last Updated: Dec 21, 2025

Measuring Mitochondrial Function of Na&#239;ve and Effector CD8 T Cells
06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

862
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.1K
Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.1K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Immune checkpoint blockers (ICB) like anti-Programmed cell death 1 (PD-1)/Programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies have revolutionized cancer therapy.
  • Despite successes, primary and acquired resistance to ICB, along with immune-related toxicities, limit their efficacy.
  • Direct immune system stimulation presents a promising avenue for overcoming these limitations and improving cancer treatment.

Purpose of the Study:

  • To review the rationale behind targeting the co-stimulatory molecule OX40 (CD134) for cancer immunotherapy.
  • To highlight the potential of combining OX40-directed therapies with other anticancer agents.
  • To explore novel strategies for enhancing anti-tumor immune responses.

Main Methods:

  • Review of existing literature on immune checkpoint inhibitors and OX40 agonists.
  • Analysis of preliminary clinical trial data for OX40-targeting agents.
  • Exploration of combination strategies involving OX40 stimulation and other cancer treatments.

Main Results:

  • ICB combinations with chemotherapy or anti-angiogenic compounds yield significant results in various tumor types.
  • Early clinical trials investigating OX40 stimulation show encouraging preliminary outcomes.
  • OX40 targeting represents a next-generation approach in cancer immunotherapy.

Conclusions:

  • OX40 stimulation is a promising strategy to enhance anti-tumor immunity.
  • Combining OX40-directed therapies with existing anticancer agents may overcome resistance and improve durable responses.
  • Further research and clinical trials are warranted to fully realize the potential of OX40-based cancer therapies.